PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized ...
Large-scale analysis of patient cohorts reveals a novel mechanism driving osteosarcoma, an aggressive paediatric bone cancer. The researchers show that this mechanism occurs in approximately 50% of ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
The researchers analysed the largest available collection of whole-genome data from osteosarcoma patients and identified a new mutation mechanism called loss-translocation-amplification (LTA) ...
Researchers published a new study, “Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution,” in Cell that they say solves the mystery of what drives the genomic ...
Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to radiation and surgery reduced relapse risk by 43%. Results showed no ...
This article first appeared with Targeted Oncology ™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS). 1 Currently, a ...
Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes. Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results